Background: CPAP enables the delivery of a greater FiO2 in hypoxic patients and has been suggested as a therapeutic option in patients with COVID-19 pneumonia. Its efficacy is as of yet unknown, and questions remain over when to use, and in which patient group. Aims: To describe outcomes in NFE patients with COVID-19 pneumonia treated with CPAP at Aintree University Hospital, Liverpool, UK. To compare these outcomes to a retrospective matched control group who did not receive CPAP therapy. Methods: NFE patients who received CPAP between March-May 2020 were identified. Each patient had radiologically confirmed COVID-19 pneumonia, with acute oxygen desaturation while receiving high flow oxygen. 21 consecutive controls were retrospectively matched by disease severity, age, sex, ethnicity and clinical frailty score (CFS). Results: There was no statistical difference between survival to discharge in the CPAP group compared to the control group (p=0.469). Key results are shown in Table 1 below: Conclusions: Our data suggests a limited role for CPAP in comorbid patients with late-stage COVID-19 pneumonia. However, we note that further investigation is required.